DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactIPO

Molbio Diagnostics IPO Listing Today: Check Expected Listing Price And Gain Based On Latest GMP

NDTV Profit 1 hr ago·17 Aug 2026, 3:11 am

Molbio Diagnostics is set to list on the stock exchanges today, marking the conclusion of its recent initial public offering (IPO). The company, which specializes in molecular diagnostics, raised funds through this public issue to support its expansion plans and strengthen its financial position. The IPO received a positive response from investors, reflecting confidence in the company's business model and growth prospects in the healthcare sector.

For investors, the listing offers an opportunity to assess the market's valuation of the company against its IPO price. The expected listing price and the potential gain will depend on the grey market premium (GMP), which indicates the demand for the shares before the listing. Retail investors should keep an eye on the trading volumes and market sentiment on the listing day to gauge the stock's performance.

Moving forward, investors should monitor Molbio Diagnostics' financial results and its ability to execute its expansion plans. The company's future growth will also depend on its ability to maintain its competitive edge in the diagnostics market. Keeping track of these factors will help investors make informed decisions regarding their holdings in the stock.